End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
8.6 CNY | -0.12% | +0.23% | -15.85% |
04-25 | Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
03-28 | Anhui Anke Biotechnology Co., Ltd. Proposes Final Dividend for 2023 | CI |
Summary
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-15.85% | 1.98B | D+ | ||
+6.58% | 39.05B | A- | ||
-11.57% | 33.74B | B- | ||
+79.15% | 28.54B | A | ||
-14.73% | 15.59B | C | ||
-6.00% | 13.69B | B- | ||
-12.55% | 11.44B | D+ | ||
+166.50% | 10.66B | D | ||
-54.80% | 9.27B | B | ||
+4.19% | 9.13B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 300009 Stock
- Ratings Anhui Anke Biotechnology (Group) Co., Ltd.